On September 28, Lianya Pharmaceutical began the subscription. The issuance price was 7 yuan/share, and the subscription limit was 18,500 shares, with a price-earnings ratio of 27.99 times. It belongs to the Shenzhen Stock Exchange, and CICC is its sponsor. According to the prospectus, the company is an R&D-driven high-tech enterprise, mainly engaged in R&D, production and sales of complex pharmaceutical preparations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.